Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 1:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dotarem (gadoterate meglumine) Clear all
Completed Phase 3 Interventional Results available

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)

NCT05915728
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Indian Wells, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 7, 2026, 1:08 PM EDT
Completed Phase 4 Interventional Results available

Crossover Comparison of MultiHance and Dotarem

NCT02070380
View directory record Official record
Conditions
Brain Disease
Interventions
MultiHance 0.1 mmol/kg, Dotarem, MultiHance 0.05 mmol/kg
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 7, 2026, 1:08 PM EDT
Withdrawn Phase 4 Interventional

A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography

NCT02163005
View directory record Official record
Conditions
Contrast Media Allergy
Interventions
Gadolinium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
56 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 7, 2026, 1:08 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors

NCT02034708
View directory record Official record
Conditions
Primary Brain Tumor
Interventions
Dotarem®, Gadovist®/Gadavist®
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2016 · Synced Oct 7, 2026, 1:08 PM EDT
Recruiting Phase 2 Interventional

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

NCT07572383
View directory record Official record
Conditions
Interstitial Lung Disease, Pulmonary Fibrosis
Interventions
[68Ga]CBP8, Gadoterate Meglumine
Drug
Lead sponsor
Peter Caravan
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 7, 2026, 1:08 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

NCT04341129
View directory record Official record
Conditions
Breast Neoplasms, Breast Diseases, Breast Fibroadenoma, Breast Cancer
Interventions
Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 7, 2026, 1:08 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

NCT03602339
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadoterate (Dotarem/Clariscan), Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 7, 2026, 1:08 PM EDT
Completed Phase 3 Interventional Results available

Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

NCT01010932
View directory record Official record
Conditions
Cerebral Arterial Diseases
Interventions
Dotarem, TOF MRA
Drug · Other
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 7, 2026, 1:08 PM EDT
Completed Phase 3 Interventional

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

NCT05915702
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Indian Wells, California • Orange, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 7, 2026, 1:08 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Severe Sepsis in Children - IMPRESS-C

NCT02598674
View directory record Official record
Conditions
Acute Kidney Injury, Chronic Kidney Disease, Hypertension
Interventions
Iodohippurate, 24 hour ambulatory Blood Pressure, Peripheral Arterial Tonometry, Pulse Wave Velocity, Gadolinium
Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
7 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 7, 2026, 1:08 PM EDT
Recruiting Phase 3 Interventional

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

NCT07348640
View directory record Official record
Conditions
Steno-occlusive Disease
Interventions
gadopiclenol, Gadoterate meglumine (Dotarem)
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 7, 2026, 1:08 PM EDT
Recruiting No phase listed Observational

Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis

NCT06265272
View directory record Official record
Conditions
Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
Interventions
Injection of a gadolinium contrast agen, Radiotracer Injection, Imaging
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 7, 2026, 1:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gadolinium Retention in Human Bone Tissue in Pediatric Patients

NCT03337594
View directory record Official record
Conditions
Gadolinium, MultiHance, Dotarem, Magnetic Resonance Imaging, Gadolinium Retention
Interventions
Pre-operative MRI with Dotarem, Pre-operative MRI with MultiHance, Surgery
Drug · Procedure
Lead sponsor
Donna Roberts
Other
Eligibility
Up to 18 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 7, 2026, 1:08 PM EDT
Recruiting Phase 2 Interventional

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

NCT05417776
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
[68Ga]CBP8, Dotarem
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 7, 2026, 1:08 PM EDT
Terminated Phase 3 Interventional Results available

Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

NCT00845702
View directory record Official record
Conditions
Renal Artery Stenosis
Interventions
Gadoterate meglumine (Dotarem), Time of Flight Magnetic Resonance Angiography
Drug · Other
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 7, 2026, 1:08 PM EDT
Withdrawn No phase listed Observational

QSM and Regional DCE MRI Permeability Using GOCART Technique

NCT03091803
View directory record Official record
Conditions
Intracranial Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadoterate Meglumine, Magnetic Resonance Imaging
Device · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 7, 2026, 1:08 PM EDT
Completed No phase listed Observational

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

NCT03910114
View directory record Official record
Conditions
Magnetic Resonance Imaging Contrast Agents
Interventions
Magnevist, Dotarem, Gadovist
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
500 participants
Timeline
1990 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 7, 2026, 1:08 PM EDT
Recruiting Phase 4 Interventional

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

NCT04373564
View directory record Official record
Conditions
Motor Function, Cognitive Function, Contrast Media
Interventions
Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol
Procedure · Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
16
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 7, 2026, 1:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Efficacy of Gadoterate Meglumine in Diagnosis of Vascular Diseases Using MRA MRA

NCT05199792
View directory record Official record
Conditions
Vascular Diseases
Interventions
Dotarem
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 7, 2026, 1:08 PM EDT
Completed Phase 3 Interventional Results available

Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

NCT01012674
View directory record Official record
Conditions
Cerebral Arterial Diseases
Interventions
Dotarem, TOF MRA
Drug · Other
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 7, 2026, 1:08 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study

NCT02783768
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, E-cigarettes
Interventions
E-cigarette, Sham, Hyperpolarized 3-Helium, Gadolinium
Device · Other · Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 7, 2026, 1:08 PM EDT
Completed No phase listed Observational

Intra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRI

NCT03023566
View directory record Official record
Conditions
Brain Diseases
Interventions
Dotarem
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 7, 2026, 1:08 PM EDT
Withdrawn Phase 4 Interventional

Use of Gadolinium in CT Pulmonary Angiography

NCT02234375
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Gadolinium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 7, 2026, 1:08 PM EDT
Recruiting Phase 2 Interventional

Advanced Imaging for Pulmonary Fibrosis

NCT06532071
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
[68Ga]CBP8, Gadoterate Meglumine
Drug
Lead sponsor
Peter Caravan
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 7, 2026, 1:08 PM EDT